SCHEMBL2227585

SCHEMBL2227585

CC(C)N(C(C)C)P(C)OCc1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
TSHR P16473 3/20 0.40
KMT2A Q03164 2/20 0.38
IDO1 P14902 1/20 0.38
AGXT P21549 1/20 0.36
ALDH1A1 P00352 2/20 0.36
CA1 P00915 1/20 0.36
CA2 P00918 1/20 0.36
CA9 Q16790 1/20 0.36
MAPK1 P28482 2/20 0.36
LMNA P02545 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
SLC6A2 P23975 3/20 0.35
TAAR1 Q96RJ0 2/20 0.35
SLC6A4 P31645 2/20 0.35
SLC6A3 Q01959 2/20 0.35
MAOA P21397 1/20 0.35
SIGMAR1 Q99720 1/20 0.35
CYP2A6 P11509 1/20 0.35
ADORA2A P29274 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL80897 0.83 TSHR (0.41) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL2252915 0.83 TSHR (0.41) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL2261012 0.80 TSHR (0.39) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL2240873 0.80 KMT2A (0.40) TSHRKMT2AIDO1ALDH1A1MAPK1
SCHEMBL24027339 0.80 TSHR (0.39) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL24027472 0.77 TSHR (0.36) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL16171402 0.76 TSHR (0.41) TSHRIDO1AGXTALDH1A1MAPK1
SCHEMBL24027553 0.74 KMT2A (0.35) TSHRKMT2AIDO1ALDH1A1CA1
SCHEMBL388026 0.73 TSHR (0.52) TSHRKMT2AIDO1AGXTALDH1A1
SCHEMBL14702031 0.73 TSHR (0.52) TSHRKMT2AIDO1AGXTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1598053-B1 Use of a composition containing at least one phosphine as majority reducing agent to remove the artificial colour of keratinic fibres OREAL (FR) 2006-12-20 EP claimed
EP-1598053-A1 Use of a composition containing at least one phosphine as majority reducing agent to remove the artificial colour of keratinic fibres L'OREAL (FR) 2005-11-23 EP claimed
US-20050251928-A1 Method for stripping artificial color from keratin fibers L'OREAL (FR) 2005-11-17 US claimed
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-12-12 US disclosed
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 SHANGHAI YAO YUAN BIOTECHNOLOGY CO., LTD. (CN) 2023-10-03 US disclosed
US-11707519-B2 Phosphorylated heptose compounds: process for their preparation and use UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND (IE) 2023-07-25 US disclosed
US-20230165771-A1 PROCESS FOR TREATING KERATIN FIBERS USING PARTICULAR AMINO ACIDS IN HIGH CONCENTRATION L'OREAL (FR) 2023-06-01 US disclosed
EP-4171490-A1 PROCESS FOR TREATING KERATIN FIBERS USING PARTICULAR AMINO ACIDS IN HIGH CONCENTRATION L'OREAL (FR) 2023-05-03 EP disclosed
WO-2022003040-A1 PROCESS FOR TREATING KERATIN FIBERS USING PARTICULAR AMINO ACIDS IN HIGH CONCENTRATION L'OREAL (FR) 2022-01-06 WO disclosed
WO-2020023628-A1 COMPOUNDS, DERIVATIVES, AND ANALOGS FOR CANCER HYGIA PHARMACEUTICALS, LLC (US) 2020-01-30 WO disclosed
WO-2017025244-A1 COSMETIC PROCESS FOR TREATING KERATIN MATERIALS L'OREAL (FR) 2017-02-16 WO disclosed
WO-2016076437-A1 COMPOSITION FOR KERATIN FIBERS L'OREAL (FR) 2016-05-19 WO disclosed
US-20150024938-A1 METALLOENZYME INHIBITOR COMPOUNDS Mycovia Pharmaceuticals, Inc. 2015-01-22 US disclosed
US-20150004666-A1 METALLOENZYME INHIBITOR COMPOUNDS VIAMET PHARMACEUTICALS, INC. (US) 2015-01-01 US disclosed
US-20130224830-A1 EGGSHELL MEMBRANE SOLUBILIZATION METHOD USING ENZYMES AMANO ENZYME INC. (JP) 2013-08-29 US disclosed
EP-2612922-A1 EGGSHELL MEMBRANE SOLUBILIZATION METHOD USING ENZYMES Amano Enzyme Inc. (JP) 2013-07-10 EP disclosed
WO-2011089985-A1 COSMETIC COMPOSITION FOR KERATIN FIBERS L'OREAL (FR) 2011-07-28 WO disclosed
EP-1598053-B1 Use of a composition containing at least one phosphine as majority reducing agent to remove the artificial colour of keratinic fibres OREAL (FR) 2006-12-20 EP disclosed
EP-1598053-A1 Use of a composition containing at least one phosphine as majority reducing agent to remove the artificial colour of keratinic fibres L'OREAL (FR) 2005-11-23 EP disclosed
US-20050251928-A1 Method for stripping artificial color from keratin fibers L'OREAL (FR) 2005-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150024938-A1 METALLOENZYME INHIBITOR COMPOUNDS MGAM, SOD1, CAT TSHR 3406/4885KMT2A 1405/4885IDO1 951/4885
US-11707519-B2 Phosphorylated heptose compounds: process for their preparation and use PPP6C, G6PD, PFKFB1 TSHR 4697/4885KMT2A 2776/4885IDO1 1089/4885
US-20230165771-A1 PROCESS FOR TREATING KERATIN FIBERS USING PARTICULAR AMINO ACIDS IN HIGH CONCENTRATION KRT18, CKAP4, VIM TSHR 4711/4885KMT2A 767/4885IDO1 3623/4885
US-11840551-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA TSHR 2816/4885KMT2A 3054/4885IDO1 1752/4885
US-20150004666-A1 METALLOENZYME INHIBITOR COMPOUNDS MMEL1, GPX1, MPO TSHR 1086/4885KMT2A 1886/4885IDO1 634/4885
US-20050251928-A1 Method for stripping artificial color from keratin fibers KRT18, DSG1, JUP TSHR 4245/4885KMT2A 165/4885IDO1 3857/4885
US-11773131-B2 Compositions and methods of modulating the immune response by activating alpha protein kinase 1 PHKA1, PHKA2, PRKCA TSHR 2816/4885KMT2A 3054/4885IDO1 1752/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.